The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Learning from the nexus of autoimmunity and cancer
Open accessAbstract
The immune system plays critical roles in both autoimmunity and cancer, diseases at opposite ends of the immune spectrum. Autoimmunity arises from loss of T cell tolerance against self, while in cancer, poor immunity against transformed self fails to control tumor growth. Blockade of pathways that preserve self-tolerance is being leveraged to unleash immunity against many tumors; however, widespread success is hindered by the autoimmune-like toxicities that arise in treated patients. Knowledge gained from the treatment of autoimmunity can be leveraged to treat these toxicities in patients. Further, the understanding of how T cell dysfunction arises in cancer can be leveraged to induce a similar state in autoreactive T cells. Here, we review what is known about the T cell response in autoimmunity and cancer and highlight ways in which we can learn from the nexus of these two diseases to improve the application, efficacy, and management of immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inhibitory receptor deficiencies or checkpoint therapies can cause or exacerbate AIDs, 37,61”
From Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A dominant role for exhausted autoantigen-specific T cells in AID patients is at odds with the current view of pro-inflammatory activated T cells driving chronic autoimmunity. 37”
From Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases (2024) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–210 of 210
Modern anti-cytokine therapy of autoimmune diseases
Astrakhantseva, I., Efimov, G., Drutskaya, M., Kruglov, A. A., & Nedospasov, S. (2014) · Biochemistry (Moscow) · doi:10.1134/s0006297914120049 · Cited by 27
Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
Besançon, M., Gris, T., Joncas, F., Picard, V., Bergeron, A., Fradet, Y., & Toren, P. (2022) · European Urology Open Science · doi:10.1016/j.euros.2022.06.007 · Cited by 26
How does Epstein-Barr virus trigger MS?
Kuchroo, V. K., & Weiner, H. L. (2022) · Immunity · doi:10.1016/j.immuni.2022.02.008 · Cited by 23
A Review of Ustekinumab in the Treatment of Psoriatic Arthritis
Roberts, J., O’Rielly, D. D., & Rahman, P. (2018) · Immunotherapy · doi:10.2217/imt-2017-0149 · Cited by 21
Pharmacogenomics for immunotherapy and immune-related cardiotoxicity
Lal, J. C., Eng, C., & Cheng, F. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa137 · Cited by 21
Patterns of Human Leukocyte Antigen Class I and Class II Associations and Cancer
Liu, Z., Derkach, A., Yu, K. J., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2292 · Cited by 19
Emerging molecular networks in Burkitt's lymphoma
Mangani, D., Roberti, A., Rizzolio, F., & Giordano, A. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24358 · Cited by 15
Self-citationEngelhardt, J., Akter, R., Loffredo, J. T., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.am2020-4552 · Cited by 12
Editorial: Modulating Cytokines as Treatment for Autoimmune Diseases and Cancer
Mortier, E., Ma, A., Malynn, B. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.608636 · Cited by 8
Planchard, D., & Leprieur, E. G. (2011) · Revue de Pneumologie Clinique · doi:10.1016/s0761-8417(11)70009-8 · Cited by 2
Flagged first, then by citations
Cited by
Sorted by citations
Saggau, C., Bacher, P., Esser, D., Rasa, M., Meise, S., Mohr, N., Kohlstedt, N., Hutloff, A., Schacht, S.-S., Dargvainiene, J., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.08.005 · Cited by 79
Metadata
- Authors
- Mangani, D., Yang, D., & Anderson, A. C.
- Affiliations
- Harvard University (US)
- Corresponding author
- Mangani, Davide
- Anderson, Ana C.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2023-02
- Volume
- 56
- Issue
- 2
- Pages
- 256-271
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC9986833
- OpenAlex
- W4320730787
- Cited by
- 33
- References
- 210
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 12 · 2023: 4
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 476 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Melanoma Research Alliance (824733)
- Brigham and Women's Hospital
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (183910)
- National Institutes of Health
- National Cancer Institute (P01CA236749, R01CA229400, R01CA187975, R01CA246653)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- autoimmunity, cancer immunotherapy, T cell tolerance, immune checkpoint blockade, T cell dysfunction, autoreactive T cells, antitumor immunity, immunotherapy toxicity management
- MeSH terms
- Autoimmune Diseases, Humans, Immune Tolerance, Neoplasms, T-Lymphocytes, Autoimmunity, Self Tolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
